Navigation Links
Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
Date:2/19/2009

MINNEAPOLIS, Feb. 19 /PRNewswire/ -- Atritech, Inc. announced the upcoming presentation of the PROTECT AF trial results comparing the WATCHMAN(R) Left Atrial Appendage (LAA) Closure Device to the current standard of care, warfarin therapy, in patients with non-valvular atrial fibrillation. The results will be unveiled at the Late Breaking Clinical Trial session during the I2 Summit Scientific Meeting at 8:30 am on March 28, 2009. The I2 Summit is part of the Annual Meeting of the American College of Cardiology (ACC) being held March 28 - 31 in Orlando, Florida.

"This is a very important clinical study comparing the WATCHMAN to warfarin in the management of patients with atrial fibrillation. We are looking forward to the presentation by Dr. David Holmes, the Principal Investigator of the PROTECT AF Trial, at the ACC," remarked Jim Bullock, President and CEO. Hand-on demonstrations of the WATCHMAN technology will be available at the Atritech booth # 2857.

In August of 2008, Atritech announced the filing of its Pre-Market Approval Application (PMA) to the Food and Drug Administration (FDA). The PMA contained the results of the PROTECT AF Clinical Trial which began enrollment in early 2005. The WATCHMAN Device continues to be implanted in a limited number of sites while the product is under review at the FDA. To date over 70 devices have been implanted in the Continued Access Registry.

Atritech's WATCHMAN LAA Closure Technology is intended as an alternative to warfarin therapy for patients with non-valvular atrial fibrillation. Patients with atrial fibrillation (a heart condition which causes the upper chambers of the heart to beat too rapidly) are at a significantly greater risk of having a stroke due to embolization of clots that may form in the LAA. Typically these patients require blood thinning medications to prevent these clots from forming in the heart. Current medical therapy requires frequent monitoring and has diet and other drug interactions and increases the risk of bleeding. The WATCHMAN device may be an effective alternative to warfarin for these patients.

About Atritech

Atritech is privately held and based in Plymouth, Minnesota. Major investors in Atritech include SplitRock Partners, Prism Venture Partners, Tullis-Dickerson Partners, , The Vector Group, Thoma Cressey Funds, SightLine Funds and Affinity Capital. For more information, visit http://www.atritech.net.


'/>"/>
SOURCE Atritech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Atritech Announces Completion of a $22 Million Equity Financing
2. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
3. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
4. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
5. Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
6. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
7. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... ... announced today the addition of an affiliate in Minneapolis-St. Paul, MN, Dr. Adam ... accelerated detox, Naltrexone therapy and aftercare planning through his Timewise Medical practice in ...
(Date:9/25/2017)... ... 2017 , ... SyncDog, Inc., the leading ISV ... will be available in a managed cloud services model, available from its new ... new enhancements including support for caller ID and network sharing for remote users, ...
(Date:9/25/2017)... Church, VA (PRWEB) , ... September 25, 2017 ... ... & Trump, **An FDAnews Webinar**, Oct. 12, 2017 — 1:30 p.m. – 3:00 ... off to a running start. Just look what’s happened in four short months:, ...
(Date:9/25/2017)... ... September 25, 2017 , ... The award is named in honor of Betty ... year the award is given to those who exemplify the mission of Community Options ... in communities of their choosing. Recent recipients of this award include Governor Tom Kean, ...
(Date:9/25/2017)... ... September 25, 2017 , ... Just ask anyone old enough ... or 1980s, with headgear so wired up and containing so much metal that jokes ... so discreet that its treatments can barely be observed. As a result, it’s now ...
Breaking Medicine News(10 mins):